Link.....
The report, "Patient Compliance, Disease Management and Consumer
Outreach," is available at
http://www.PharmaDiseaseManagement.com . The report identifies several key strategies and campaigns that top companies have successfully implemented to help boost both patient compliance and their companies' bottom-lines. The study contains more than 50 metrics and business practices from top companies including Pfizer, Merck, Aventis,
GlaxoSmithKline, Bristol-Myers Squibb, Novartis and Eli Lilly.
"The non-compliance rates are unacceptable, and pose risks to all people involved," says senior analyst Eric Bolesh. "Unfilled prescriptions result in major health risks for patients, and cause pharmaceutical companies to lose big money. Cutting Edge Information's report shows drug companies how to implement drug management tools and improve non-compliance and customer
lifetime value."
Patient non-compliance is a growing issue that annually contributes to 125,000 deaths and up to 20% of all hospital and nursing home admissions. As the effects of patient non-compliance also have a tremendous negative impact on the pharmaceutical industry's bottom line, pharmaceutical companies have
taken several steps to help improve patient compliance, particularly by initiating disease management programs to assist patients in their personal healthcare.
According to the report, key compliance challenges include the following "big-five" issues:
- The patient fails to fill initial prescription
- The patient takes an incorrect dosage
- The patient takes medication at the wrong time
- The patient forgets to take one or more doses
- The patient stops taking the medication too soon